menu
    • menu
    [{"orgOrder":0,"company":"NEXGEL Advanced Hydrogel Solutions","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Musculoskeletal","country":"U.S.A","productType":"Other Small Molecule","year":"2022","type":"Inapplicable","leadProduct":"Diclofenac","moa":"COX-1\/COX2","graph1":"Musculoskeletal","graph2":"Undisclosed","graph3":"NEXGEL Advanced Hydrogel Solutions","amount2":0,"highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"Musculoskeletal","amount2New":0,"dosageForm":"Topical Patch","sponsorNew":"NEXGEL Advanced Hydrogel Solutions \/ Inapplicable","highestDevelopmentStatusID":"1","companyTruncated":"NEXGEL Advanced Hydrogel Solutions \/ Inapplicable"},{"orgOrder":0,"company":"Delpor","sponsor":"National Institutes of Health","pharmaFlowCategory":"D","therapeuticArea":"Musculoskeletal","country":"U.S.A","productType":"Other Small Molecule","year":"2021","type":"Funding","leadProduct":"Tizanidine HCl","moa":"Adrenergic-alpha-2 receptor","graph1":"Musculoskeletal","graph2":"Undisclosed","graph3":"Delpor","amount2":0,"highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"Musculoskeletal","amount2New":0,"dosageForm":"Implant","sponsorNew":"Delpor \/ National Institutes of Health","highestDevelopmentStatusID":"1","companyTruncated":"Delpor \/ National Institutes of Health"},{"orgOrder":0,"company":"Bone Therapeutics","sponsor":"Implant Therapeutics","pharmaFlowCategory":"D","therapeuticArea":"Musculoskeletal","country":"BELGIUM","productType":"Cell and Gene therapy","year":"2021","type":"Partnership","leadProduct":"Undisclosed","moa":"Undisclosed","graph1":"Musculoskeletal","graph2":"Undisclosed","graph3":"Bone Therapeutics","amount2":0,"highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"Musculoskeletal","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Bone Therapeutics \/ Implant Therapeutics","highestDevelopmentStatusID":"1","companyTruncated":"Bone Therapeutics \/ Implant Therapeutics"},{"orgOrder":0,"company":"Enveric Biosciences","sponsor":"Restoration Biologics","pharmaFlowCategory":"D","therapeuticArea":"Musculoskeletal","country":"U.S.A","productType":"Controlled Substance","year":"2025","type":"Licensing Agreement","leadProduct":"Undisclosed","moa":"CB\/COX-2","graph1":"Musculoskeletal","graph2":"Undisclosed","graph3":"Enveric Biosciences","amount2":0.059999999999999998,"highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"Musculoskeletal","amount2New":0.059999999999999998,"dosageForm":"Undisclosed","sponsorNew":"Enveric Biosciences \/ Restoration Biologics","highestDevelopmentStatusID":"1","companyTruncated":"Enveric Biosciences \/ Restoration Biologics"},{"orgOrder":0,"company":"Mundipharma","sponsor":"Biosolution","pharmaFlowCategory":"D","therapeuticArea":"Musculoskeletal","country":"GERMANY","productType":"Cell and Gene therapy","year":"2020","type":"Agreement","leadProduct":"Chondrocytes","moa":"Undisclosed","graph1":"Musculoskeletal","graph2":"Undisclosed","graph3":"Mundipharma","amount2":0,"highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"Musculoskeletal","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Mundipharma \/ Biosolution","highestDevelopmentStatusID":"1","companyTruncated":"Mundipharma \/ Biosolution"},{"orgOrder":0,"company":"Nestle Health Sciences SA","sponsor":"Bioiberica","pharmaFlowCategory":"D","therapeuticArea":"Musculoskeletal","country":"SWITZERLAND","productType":"Other Small Molecule","year":"2020","type":"Partnership","leadProduct":"Hyaluronic Acid","moa":"||Collagen synthesis","graph1":"Musculoskeletal","graph2":"Undisclosed","graph3":"Nestle Health Sciences SA","amount2":0,"highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"Musculoskeletal","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Nestle Health Sciences SA \/ Bioiberica","highestDevelopmentStatusID":"1","companyTruncated":"Nestle Health Sciences SA \/ Bioiberica"},{"orgOrder":0,"company":"InGeneron","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Musculoskeletal","country":"U.S.A","productType":"Cell and Gene therapy","year":"2020","type":"Inapplicable","leadProduct":"Autologous Adipose-Derived Regenerative Cell","moa":"Undisclosed","graph1":"Musculoskeletal","graph2":"Undisclosed","graph3":"InGeneron","amount2":0,"highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"Musculoskeletal","amount2New":0,"dosageForm":"Injection","sponsorNew":"InGeneron \/ Inapplicable","highestDevelopmentStatusID":"1","companyTruncated":"InGeneron \/ Inapplicable"}]

    Find Novel Musculoskeletal Drugs in Clinical Development

    Xls
    Filters Filter
    ×
    FILTER:
    filter
    Company Name
      filter

      Year

        filter

        DEALS // DEV.

          filter

          Country

            filter
            Sponsor
              filter

              Therapeutic Area

                filter

                Study Phase

                  filter

                  Deal Type

                    filter

                    Product Type

                      filter

                      Dosage Form

                        filter

                        Lead Product

                          filter

                          Target

                            Loading...
                            refresh Filters
                            refresh Reset Filter
                            refresh Reset Filter
                            price-trend All Developments

                            Therapeutic Area by Lead Product

                            Study Phase by Lead Product

                            Company by Lead Product

                            Top Deals by Deal Size (USD bn)

                            01

                            Enveric Biosciences

                            U.S.A arrow
                            AACR Annual meeting
                            Not Confirmed

                            Enveric Biosciences

                            U.S.A arrow
                            AACR Annual meeting
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Undisclosed

                            Therapeutic Area : Musculoskeletal

                            Study Phase : Undisclosed

                            Sponsor : Restoration Biologics

                            Deal Size : $61.0 million

                            Deal Type : Licensing Agreement

                            DEALS_DEV arrow-down

                            Enveric, Restoration Bio Sign Licensing Deals for Joint Disease Treatments

                            Details : Under the licensing agreement, Restoration will gain the rights of cannabinoid-COX-2 conjugate compounds. It is being used for the joint pathology, such as osteoarthritis and rheumatoid arthritis.

                            Product Name : Undisclosed

                            Product Type : Controlled Substance

                            Upfront Cash : Undisclosed

                            February 04, 2025

                            Lead Product(s) : Undisclosed

                            Therapeutic Area : Musculoskeletal

                            Highest Development Status : Undisclosed

                            Sponsor : Restoration Biologics

                            Deal Size : $61.0 million

                            Deal Type : Licensing Agreement

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            02

                            NEXGEL Advanced Hydrogel Solutions

                            U.S.A arrow
                            AACR Annual meeting
                            Not Confirmed

                            NEXGEL Advanced Hydrogel Solutions

                            U.S.A arrow
                            AACR Annual meeting
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Diclofenac

                            Therapeutic Area : Musculoskeletal

                            Study Phase : Undisclosed

                            Sponsor : Inapplicable

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            DEALS_DEV arrow-down

                            NEXGEL Reports Positive Results from Proof-of-Concept Study for its Diclofenac Hydrogel Pain Treatment

                            Details : Diclofenac hydrogel patches are a nonsteroidal anti-inflammatory drug (NSAIDs) products that are used to treat short-term pain due to minor strains, sprains and bruises.

                            Product Name : Undisclosed

                            Product Type : Other Small Molecule

                            Upfront Cash : Inapplicable

                            October 25, 2022

                            Lead Product(s) : Diclofenac

                            Therapeutic Area : Musculoskeletal

                            Highest Development Status : Undisclosed

                            Sponsor : Inapplicable

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            03

                            Delpor

                            U.S.A arrow
                            AACR Annual meeting
                            Not Confirmed

                            Delpor

                            U.S.A arrow
                            AACR Annual meeting
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Tizanidine HCl

                            Therapeutic Area : Musculoskeletal

                            Study Phase : Undisclosed

                            Sponsor : National Institutes of Health

                            Deal Size : $2.5 million

                            Deal Type : Funding

                            DEALS_DEV arrow-down

                            Delpor Advances Pipeline to Include Spasticity Maintenance Therapy with $2.5 Million NIH Grant for Tizanidine ...

                            Details : Proceeds from the financing will be used for the advancement of the company’s tizanidine implant product (DLP-208) for moderate-severe spasticity. DLP-208 can provide sustained therapy for several months, while only requiring a 10-minute procedure in a...

                            Product Name : DLP-208

                            Product Type : Other Small Molecule

                            Upfront Cash : Undisclosed

                            November 16, 2021

                            Lead Product(s) : Tizanidine HCl

                            Therapeutic Area : Musculoskeletal

                            Highest Development Status : Undisclosed

                            Sponsor : National Institutes of Health

                            Deal Size : $2.5 million

                            Deal Type : Funding

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            04

                            Bone Therapeutics

                            Belgium arrow
                            AACR Annual meeting
                            Not Confirmed

                            Bone Therapeutics

                            Belgium arrow
                            AACR Annual meeting
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Undisclosed

                            Therapeutic Area : Musculoskeletal

                            Study Phase : Undisclosed

                            Sponsor : Implant Therapeutics

                            Deal Size : Undisclosed

                            Deal Type : Partnership

                            DEALS_DEV arrow-down

                            Bone Therapeutics Signs Research Partnership with Implant Therapeutics to Access Induced Pluripotent Stem Cell...

                            Details : Bone Therapeutics has partnered with Implant Therapeutics to gain access to iPSC derived, genetically engineered MSCs. These specific single source MSCs are highly standardized, are expandable and scalable.

                            Product Name : Undisclosed

                            Product Type : Cell and Gene therapy

                            Upfront Cash : Undisclosed

                            September 28, 2021

                            Lead Product(s) : Undisclosed

                            Therapeutic Area : Musculoskeletal

                            Highest Development Status : Undisclosed

                            Sponsor : Implant Therapeutics

                            Deal Size : Undisclosed

                            Deal Type : Partnership

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            05

                            InGeneron

                            U.S.A arrow
                            AACR Annual meeting
                            Not Confirmed

                            InGeneron

                            U.S.A arrow
                            AACR Annual meeting
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Autologous Adipose-Derived Regenerative Cell

                            Therapeutic Area : Musculoskeletal

                            Study Phase : Undisclosed

                            Sponsor : Inapplicable

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            DEALS_DEV arrow-down

                            Study Finds InGeneron's Regenerative Cell Therapy to Significantly Reduce Pain and Improve Shoulder Function

                            Details : Study reveals favorable results using regenerative cells isolated from patients’ own body fat prepared with the Transpose® RT System in the Journal of Orthopaedic Surgery and Research.

                            Product Name : Undisclosed

                            Product Type : Cell and Gene therapy

                            Upfront Cash : Inapplicable

                            July 04, 2020

                            Lead Product(s) : Autologous Adipose-Derived Regenerative Cell

                            Therapeutic Area : Musculoskeletal

                            Highest Development Status : Undisclosed

                            Sponsor : Inapplicable

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            06

                            Nestle Health Sciences SA

                            Switzerland arrow
                            AACR Annual meeting
                            Not Confirmed

                            Nestle Health Sciences SA

                            Switzerland arrow
                            AACR Annual meeting
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Hyaluronic Acid,Type II Collagen,Undisclosed

                            Therapeutic Area : Musculoskeletal

                            Study Phase : Undisclosed

                            Sponsor : Bioiberica

                            Deal Size : Undisclosed

                            Deal Type : Partnership

                            DEALS_DEV arrow-down

                            Nestlé Health Science Partners with Bioiberica to Deliver Innovative Nutrition in Joint Health and Mobility

                            Details : Nestlé Health Science is incorporating Bioiberica’s patented ingredient, Mobilee®, into its MERITENE® Mobilis® joint-health drink mix.

                            Product Name : Meritene Mobilis

                            Product Type : Other Small Molecule

                            Upfront Cash : Undisclosed

                            June 16, 2020

                            Lead Product(s) : Hyaluronic Acid,Type II Collagen,Undisclosed

                            Therapeutic Area : Musculoskeletal

                            Highest Development Status : Undisclosed

                            Sponsor : Bioiberica

                            Deal Size : Undisclosed

                            Deal Type : Partnership

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            07

                            Mundipharma

                            Germany arrow
                            AACR Annual meeting
                            Not Confirmed

                            Mundipharma

                            Germany arrow
                            AACR Annual meeting
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Chondrocytes

                            Therapeutic Area : Musculoskeletal

                            Study Phase : Undisclosed

                            Sponsor : Biosolution

                            Deal Size : Undisclosed

                            Deal Type : Agreement

                            DEALS_DEV arrow-down

                            Mundipharma, Biosolution to market CartiLife in South Korea

                            Details : Under the agreement, Mundipharma obtains the rights to market and distribute CartiLife® in South Korea.

                            Product Name : Undisclosed

                            Product Type : Cell and Gene therapy

                            Upfront Cash : Undisclosed

                            June 01, 2020

                            Lead Product(s) : Chondrocytes

                            Therapeutic Area : Musculoskeletal

                            Highest Development Status : Undisclosed

                            Sponsor : Biosolution

                            Deal Size : Undisclosed

                            Deal Type : Agreement

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth